Cytochrome P4501A1 (CYP1A1) has been implicated in the conversion of numerous polycyclic aromatic hydrocarbons into electrophilic species capable of binding covalently to DNA and has therefore been postulated to be involved in the initiation of carcinogenesis. The expression of CYP1A1 protein appears not to be constitutive, but is readily inducible by aryl hydrocarbon (Ah) receptor ligands in a majority of tissues of experimental animals, especially the liver. To date, there is conflicting evidence for the expression or inducibility of CYP1A1 protein in human liver. In this present study, we report the detection of CYP1A1 in all 20 human liver microsomal samples tested by standard western immunoblotting with chemiluminescent detection using a specific monoclonal antibody (mAb 1-12-3) directed against a marine fish (scup) cytochrome P450E. mAb 1-12-3 has been shown previously to specifically recognize CYP1A1 in mammals. This system consistently demonstrated a detection sensitivity as low as 0.01-0.025 pmol CYP1A1 per lane. In the samples where CYP1A1 protein levels were quantitated, CYP1A1 ranged from~0.4 to 5 pmol CYP1A1/mg microsomal protein. Additionally, the inducibility of CYP1A1 protein was demonstrated by incubating precision-cut human liver slices in dynamic organ culture for up to 96 h in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The specificity of mAb 1-12-3 was tested using several purified human and rat cytochrome P450s to ensure that the protein being detected was CYP1A1. mAb 1-12-3 did not cross-react with human CYP1A2 or CYP3A4 or rat CYP1B1, but did strongly recognize CYP1A1. However, there was a very weak cross-reactivity of mAb 1-12-3 with human CYP2E1, 75-fold less compared with CYP1A1. In order to confirm CYP1A1 as the immunoreactive protein detected in human liver, microsomal samples were subjected to two-dimensional electrophoresis involving isoelectric focusing followed by SDS-PAGE and immunoblotting. Utilizing mAb 1-12-3, the human liver microsomal samples displayed an immunoblotting profile matching that obtained from a microsomal preparation from a AHH-1 TK ϩ/-cell line expressing solely human CYP1A1 and differing from the profile obtained using a polyclonal antibody directed against CYP2E1 and cells expressing CYP2E1. Further- 
Introduction
The cytochrome P450 monooxygenase system is a superfamily of enzymes which play a critical role in the metabolism of xenobiotics and endogenous compounds. This system is responsible for the majority of phase I metabolism, which is the initial step in deactivation and eventual removal of substances from the body. The activity of this system can also occasionally result in the activation of a compound into a carcinogenic species capable of covalently binding to DNA and forming adducts. The formation of DNA adducts is believed to be one of the primary steps in the initiation of chemically induced carcinogenesis (1) . It is now apparent that the majority of xenobiotic carcinogens require metabolic activation in order to elicit their carcinogenic effects. There have been at least 25 human cytochrome P450 enzymes identified (2) . Five of these cytochromes have been implicated for most of the metabolic activation of xenobiotics: cytochrome P450s (CYP*) 1A1, 1A2, 1B1, 2E1 and 3A4 (3, 4) . Specifically, CYP1A1 is of particular interest because it is the most active of the cytochromes in metabolizing polycyclic aromatic hydrocarbons (PAHs) into reactive species (4, 5) . Moreover, concerns are heightened due to the fact that CYP1A1 is readily inducible in experimental animals following exposure to environmental pollutants, such as the PAHs, polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans and polychlorinated biphenyls.
The exact relationship between CYP1A1 protein levels and chemically induced carcinogenesis remains an area of continued research and debate, due to the occurrence of a multitude of conflicting studies. Evidence has been put forth both supporting and opposing an increased risk of carcinogenesis with elevated levels of CYP1A1 expression. In support of this conclusion, increased expression or inducibility of CYP1A1 has been implicated in higher levels of DNA adducts, an initial necessary step in the carcinogenic process, and/or risk of lung cancer (3, (6) (7) (8) (9) as well as increased risk of cancer of the larynx and oral cavity (3, 10, 11) . In addition, a restriction fragment length polymorphism located in the 3Ј-non-coding region of CYP1A1 (MspI) identified in the Japanese population has been associated with an increase in CYP1A1 activity and an elevated risk of lung cancer (12) (13) (14) . The MspI polymorphism combined with a lack of glutathione S-transferase-µ1 activity also resulted in a significantly higher risk of lung cancer in Asian populations (15) (16) (17) . Recently, this polymorphism has been linked with a higher risk of endometrial cancer in Caucasians (18) . Another polymorphism of the CYP1A1 gene, linked to the MspI polymorphism, has been identified in exon 7 and results in a substitution of valine for isoleucine in the heme binding region at residue 462 (19) . It has been reported that this polymorphism in exon 7 results in higher enzymatic activity (~1.5-fold), as demonstrated by expression of both CYP1A1 alleles in yeast (20) . Moreover, the exon 7 polymorphism has been linked to a higher CYP1A1 inducibility in lymphocytes (21) and is also associated with an elevated risk of developing lung and endometrial cancers (18, 22) . Numerous studies in mice also support an increased risk of carcinogenesis associated with elevated CYP1A1. Mouse strains differing in their genetic responsiveness to CYP1A1 inducibility differed in their susceptibility to PAHinduced carcinogenicity, with the more highly responsive being more susceptible (23) (24) (25) . More recently, reports focusing on increased mutagenicity and oxidative DNA damage demonstrated a direct relationship with CYP1A1 expression (26) (27) (28) . Even very small elevations in CYP1A1 expression resulted in significant increases in mutagenicity (26) .
In opposition to the aforementioned studies, a correlation between CYP1A1 inducibility, MspI polymorphism and lung cancer risk was not observed in European, Norwegian, American or Finnish populations (29) (30) (31) (32) and no association was found between individuals with a high CYP1A1 inducible phenotype and lung cancer in other studies (33) (34) (35) (36) . Moreover, lack of the MspI polymorphism was associated with an increase, not a decrease, in the number of DNA adducts in chimney sweeps (37) . In addition, reports regarding the polymorphism at exon 7 have not always demonstrated an association with lung cancer (32) . Following expression of the mutant allele at exon 7 in Escherichia coli and yeast, it was concluded that the exon 7 polymorphism did not result in significant alterations in CYP1A1 metabolic activity (38, 39) . One of the major obstacles preventing a clear association between elevated CYP1A1 levels and an increased risk of carcinogenesis are reports of a protective effect of pretreatment with CYP1A1 inducers against PAH-induced carcinogenesis (40) (41) (42) (43) (44) . Furthermore, CYP1A1 has also been demonstrated to detoxify compounds, such as certain PAHs, into inactive metabolites (45, 46) . Despite the uncertainty of the exact involvement of CYP1A1 in carcinogenesis, it is still believed to play a significant role. Therefore, it is important to determine the expression of CYP1A1 in humans and its potential for inducibility, especially in the liver, the major site quantitatively for xenobiotic metabolism.
Previously, numerous studies have examined the expression of CYP1A1 in human liver. A majority of these studies reported no detectable CYP1A1 protein, as determined by western immunoblotting (47) (48) (49) (50) (51) (52) (53) , and it has therefore been concluded that CYP1A1 protein is not expressed in human liver. However, the presence of CYP1A1 mRNA has been detected in human liver (54) (55) (56) (57) (58) and the inducibility of CYP1A1 mRNA and ethoxyresorufin O-deethylaase (EROD) activity, a marker for CYP1A1 activity, have been shown in isolated human hepatocytes (52, 59, 60) . Additionally, EROD activity was induced in vivo, as determined from hepatic human liver biopsy specimens, following exposure to the clinically used proton pump inhibitor omeprazole (52) . Moreover, omeprazole and another proton pump inhibitor, lansoprazole, were shown by western immunoblotting using an antirabbit CYP1A1 antibody to induce a protein, believed to be CYP1A1, in isolated human hepatocytes in primary culture (61) . While there has not been any convincing evidence, as yet, for CYP1A1 protein expression in human liver in vivo, there are a few reports of the detection of a protein in human liver that could possibly be CYP1A1 (54, 62, 63 ). In the current study, using a combination of a monoclonal antibody and western immunoblotting with chemiluminescent detection, which resulted in a highly sensitive system, we report expression of CYP1A1 protein in all human liver samples examined. Additionally, we demonstrate inducibility of CYP1A1 protein by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in precisioncut human liver slices incubated in dynamic organ culture, an in vitro model we have recently validated for studying CYP1A1 induction (64) .
Materials and methods

Antibodies and cytochrome P450 proteins
The preparation and initial characterization of mAb 1-12-3 has been previously described (65) . Rabbit polyclonal antibodies directed against human CYP2E1 and purified recombinant human CYP1A1, CYP1A2, CYP2E1 and CYP3A4 proteins were generously provided by F.P.Guengerich (Vanderbilt University School of Medicine, Nashville, TN). The antipeptide anti-human CYP1A1 was generously provided by R.Edwards (Imperial School of Medicine, London). Recombinant mouse CYP1B1 protein was generously provided by C.R.Jefcoate (University of Wisconsin Medical School, Madison, WI). Microsomes derived from AHH-1 TK ϩ/-cells expressing either human CYP1A1 or CYP2E1 protein were purchased from Gentest (Woburn, MA). Yeast microsomes expressing either human CYP1A1 or CYP1A2 were generously provided by H.P.Eugster (Institute of Toxicology, Schwerzenbach, Switzerland).
Microsomal preparation
Frozen specimens of human liver were obtained from F.P.Guengerich. Additional tissue was obtained from IIAM, the Anatomical Gift Foundation and Upstate New York Transplant Services. The tissue was stored at -70°C until preparation of microsomes. The liver microsomes were prepared at 4°C as previously described (66) . The microsomal pellet was resuspended with reconstituting buffer (10 mM Tris, 20% v/v glycerol, 1 mM EDTA, pH 7.4 at 4°C) and stored at -70°C.
Liver slices were weighed and stored at -70°C following incubation in dynamic organ culture. Microsomes were prepared at 4°C from the liver slices essentially as described by Cinti et al. (67) . The microsomal pellet was resuspended in reconstituting buffer using a sonicator and stored at -70°C.
The protein concentrations were determined by the method of Bradford (68) .
Liver slice preparation and incubation
Fresh liver was obtained within 36 h of procurement from human liver donors when the tissue could not be transplanted (IIAM and the Anatomical Gift Foundation). Livers were perfused with UW solution and shipped on wet ice. Donor A was a 37-year-old male Caucasian with no history of alcohol use, who smoked 1 pack of cigarettes/day for 15 years and died of head trauma. Donor B was a 55-year-old male Caucasian with no history of alcohol or tobacco use, who died of meningioma with brain stem compression. Precisioncut human liver slices were prepared essentially as described by Smith et al. (69) , with modifications described previously (64) . The slices were incubated in dynamic organ culture for 24 h in Waymouth's medium (supplemented with 25 mM HEPES, 25 mM glucose, 5% horse serum, 5% fetal calf serum, and penicillin and streptomycin) containing TCDD dissolved in dimethylsulfoxide (0.1% in medium) or vehicle alone and subsequently incubated for up to an additional 72 h in TCDD-free medium. The viability of the slices was determined by measuring intracellular K ϩ content using a flame photometer (64) . Intracellular K ϩ contents of 40 µmol/g or greater were considered viable tissue.
Electrophoresis and immunoblotting SDS-PAGE was performed essentially according to the method of Laemmli (70) . CYP1A1 protein was quantitated in human liver microsomes by western immunoblotting as described by Guengerich et al. (71) using chemiluminescent detection. Proteins were transferred to an Immobilon PVDF membrane (Millipore, Bedford, MA). The non-specific binding sites were blocked with 10% non-fat milk and the blots were incubated with primary antibody. Two different chemiluminescent detection systems were utilized. One employed secondary antibodies conjugated with biotin, which was subsequently detected with streptavidin labeled with peroxidase and developed with Lumi-Glo (Kirkgaard and Perry, Gaithersburg, MD) chemiluminescent substrate. The other utilized secondary antibodies conjugated with alkaline phosphatase and was developed with CDP-Star (Tropix, Bedford, MA) chemiluminescent substrate. Both chemiluminescent substrates were used according to the manufacturers' protocol. The luminescence produced was detected by exposure to X-ray film and the intensity of the bands determined by laser densitometry (GS-700; Bio-Rad, Hercules, CA). A standard curve of known amounts of purified CYP1A1 was incorporated on blots to allow for accurate quantitation. Two-dimensional gel electrophoresis was performed following the basic procedure described by Bonfils and Combalbert (72) . The procedure was comprised of non-equilibrium pH gradient electrophoresis (NEPHGE) (73) followed by SDS-PAGE and immunoblotting. The polymerization solution for the isoelectric focusing (IEF) gels (15 ml) comprised 8.25 g urea, 1.995 ml 30% acrylamide, 3 ml 10% Tergitol NP-10, 0.75 ml 10% CHAPS, 2.25 ml water, 750 µl ampholytes pH 3-10 (Sigma Chemical Co., St Louis, MO), 37.5 µl 10% ammonium persulfate and 12 µl N,N,NЈ,NЈ-tetramethylethylenediamine. Phosphoric acid (0.01 nM) and 0.02 nM sodium hydroxide were the electrode solutions used at the anode and cathode respectively. Microsomal samples were dissolved in sample buffer (9.5 M urea, 5% ampholytes pH 3-10, 5% β-mercaptoethanol, 2% Tergitol NP-10 and 0.5% CHAPS), loaded on the anodic end of the gel and covered with overlay solution (9 M urea, 2.5% ampholytes 3-10 and 0.001% bromophenol blue). The gels were run for 15 min at 300 V followed by 2 h at 500 V. After the NEPHGE was completed the tubes were extruded and stored at -70°C in SDS-PAGE sample buffer (0.25 M Tris-HCl pH 6.8, 5% w/v SDS, 0.05% bromophenol blue, 10% v/v glycerol and 5% v/v β-mercaptoethanol) until the subsequent SDS-PAGE was performed. Prior to running the second dimension a gel tube was thawed and allowed to equilibrate for 2 h at room temperature. Following equilibration, the tube was placed on top of a 10% SDS-PAGE gel and covered with an overlay solution [0.08 g agarose, 5.83 ml water, 0.417 ml β-mercaptoethanol and 2.08 ml 4ϫ buffer (12.5 ml 0.5 M Tris-HCl pH 6.8, 8 ml 25% SDS, 2.5 ml 100 mM EDTA pH 7, 2 ml 100 mM EGTA pH 7). The SDS-PAGE and immunoblotting and chemiluminescent detection were performed as described above. Enzymatic activity EROD activity was determined in liver microsomes by the fluorometric assay described by Prough et al. (74) . The wavelengths for excitation and emission were 530 and 585 nM respectively. The rate of fluorescence change was recorded prior to and after addition of a known quantity of resorufin.
Analysis of CYP1A1 genotypes
The MspI polymorphism of the 3Ј-non-coding region of the CYP1A1 gene was characterized by restriction fragment length polymorphism PCR as described by Sivaraman et al. (75) . The polymorphism in exon 7 (residue 462) was analyzed by allele-specific PCR as described by Hayashi et al. (14) .
Results
The expression of CYP1A1 protein in human liver was determined by western immunoblotting utilizing a specific monoclonal antibody (mAb 1-12-3) directed against a marine fish (scup) cytochrome P450E. Scup cytochrome P450E has been confirmed to be analogous to CYP1A1 in mammals by cDNA cloning and sequencing (76) and mAb 1-12-3 has been previously shown to be specific for both rat CYP1A1 and scup cytochrome P450E (65, 77) . The combination of mAb 1-12-3 and western immunoblotting with chemiluminescent detection resulted in a highly sensitive system, as demonstrated in Figure  1 . A standard curve consisting of varying levels of purified recombinant human CYP1A1 protein detected by western immunoblotting with mAb 1-12-3 is shown. The sensitivity was routinely between 0.01 and 0.025 pmol recombinant human CYP1A1 protein per lane. The specificity of mAb 1-12-3 was initially investigated by testing the cross-reactivity of the antibody against human CYP1A1 and CYP1A2 (Figure 2). Due to the fact that these cytochromes are highly homologous (~80%) (78), polyclonal antibodies directed against CYP1A1 commonly cross-react with CYP1A2. Additionally, since CYP1A1 and CYP1A2 display similar mobility on SDS-PAGE gels and CYP1A2 is constitutively expressed at significantly higher levels, detection of CYP1A1 with antibodies that cross-react with CYP1A2 is not feasible. However, as demonstrated in Figure 2 , mAb 1-12-3 specifically recognizes purified recombinant human CYP1A1 protein and microsomal preparations from yeast expressing human In order to assess the inducibility of CYP1A1 protein in human liver, we utilized a recently validated in vitro model (64) . Precision-cut human liver slices were incubated in dynamic organ culture for 24-96 h in the presence of 0-10 nM TCDD. As demonstrated by western immunoblotting of a human liver sample (Figure 4) , precision-cut human liver slices incubated for 24 h displayed a small concentrationdependent elevation in CYP1A1 protein (Figure 4 ), while incubation of liver slices for 96 h resulted in a more pronounced concentration-dependent induction of CYP1A1 expression ( Figure 5A ). However, the CYP1A1 protein induction elicited at 96 h by TCDD was variable and did not always result in a dramatic increase in CYP1A1 expression, as illustrated in a different liver specimen ( Figure 5B ), although induction was still observed. Neither liver specimen (A and B) contained the MspI or exon 7 polymorphisms. Additionally, there does not appear to be any association between donor history, liver procurement and measures of viability of the liver slices and differences in the degree of inducibility of CYP1A1 by TCDD in the two liver specimens. The donor histories, measures of viability (intracellular K ϩ ) and fat content (Ͻ30%) were similar in the two specimens. In order to confirm the identity of the induced protein as CYP1A1, a specific polyclonal antipeptide antibody directed against human CYP1A1 (47) was utilized in western immunoblotting. This antibody lacked the sensitivity obtained with mAb 1-12-3 in our system, but nonetheless a single protein band corresponding to CYP1A1 was detected in the high TCDD exposure groups ( Figure 6 ). In human liver microsomes from untreated and unincubated samples and microsomes from human liver slices incubated in dynamic organ culture with low concentrations of TCDD (0.01 nM) the antipeptide antibody detected no clear definitive protein bands (Figure 6 ). However, faint blurry bands, possibly CYP1A1, were seen ( Figure 6 ). Further evidence for CYP1A1 protein induction is gained from the measurement of CYP1A1-mediated EROD activity. As demonstrated by Figure 7 , there is an~5-fold induction of EROD activity in human liver slices incubated for 24 h in the presence of 10 nM TCDD compared with the control. Likewise, CYP1A1 protein was induced (~2.5-fold), while CYP1A2 protein displayed little change.
Due to the inability to clearly detect CYP1A1 protein with the polyclonal antipeptide antibody in untreated human liver microsomes, concerns were raised about the possible crossreaction of mAb 1-12-3 with other constitutively expressed cytochrome P450s. Therefore, the cross-reactivity of mAb 1-12-3 was tested against purified recombinant human CYP1A1, CYP1A2, CYP2E1 and CYP3A4, as well as rat CYP1B1, by western immunoblotting. Figure 8A demonstrates the specifi- city of mAb 1-12-3. Clearly, mAb 1-12-3 only recognized CYP1A1 following normal exposures of the X-ray film. Upon extreme over-exposure a faint band was detected in the CYP2E1 lane (not shown). This cross-reactivity was further characterized by western immunoblotting, as demonstrated by Figure 8B . mAb 1-12-3 strongly recognized recombinant purified human CYP1A1 and weakly recognized recombinant purified human CYP2E1 (~75-fold less).
There is little concern that the induced protein detected by both mAb 1-12-3 and the antipeptide antibody was CYP2E1 because expression of CYP2E1 is not increased by TCDD treatment in this in vitro system, as determined by western immunoblotting with antibodies directed against CYP2E1 (unpublished data). However, since mAb 1-12-3 displayed a cross-reactivity to CYP2E1, although very weak, the possibility that the constitutively expressed protein detected in human liver microsomes was CYP2E1 was investigated by twodimensional gel electrophoresis employing IEF followed by SDS-PAGE. As demonstrated in Figure 9 , mAb 1-12-3 recognized a single protein in human liver microsomes, which migrated similarly to the CYP1A1 standard. Additionally, the shapes of the proteins closely matched one another. Moreover, both the CYP1A1 standard and the protein identified in human liver microsomes by mAb 1-12-3 migrated differently from the CYP2E1 standard probed with a polyclonal antibody directed against human CYP2E1. When the CYP2E1 standard was probed with mAb 1-12-3, no bands or spots were observed (data not shown). Furthermore, mAb 1-12-3 identified a single protein, depicted by a single spot migrating as the CYP1A1 standard when the CYP1A1 and CYP2E1 standards were combined. When this standard combination was probed with antibody against CYP2E1, a single band corresponding to CYP2E1 was observed. Thus, the two-dimensional immunoblots reinforce the conclusion of CYP1A1 protein expression in human liver.
Discussion
CYP1A1 has been implicated as playing a role in the initiation of carcinogenesis. In experimental animals, CYP1A1 appears not to be constitutively expressed, but is readily inducible by aryl hydrocarbon receptor ligands, especially in the liver, the major site quantitatively for xenobiotic metabolism. To date, the presence or expression of CYP1A1 protein in human liver and its inducibility in vivo has not been firmly established. In the present study, we demonstrate by western immunoblotting with mAb 1-12-3 the presence of a protein in all human microsomal samples tested, which migrates identically to a recombinant human CYP1A1 standard. mAb 1-12-3 has previously been shown to be specific for rat CYP1A1 and scup cytochrome P450E, a cytochrome analogous to CYP1A1 in mammals (65, 76, 77) . In support of this specificity, we show that mAb 1-12-3 strongly recognized recombinant human 1365 CYP1A1 protein while displaying no cross-reaction to recombinant human CYP1A2 and CYP3A4 or rat CYP1B1 and only a very weak reaction to recombinant human CYP2E1.
In order to verify the protein detected in human liver as CYP1A1 and not CYP2E1, we utilized two-dimensional electrophoresis involving IEF followed by SDS-PAGE and immunoblotting. Two-dimensional electrophoresis was employed because human CYP1A1 and CYP2E1 migrate nearly identically on standard SDS-PAGE gels and it is therefore not possible to distinguish antibody cross-reaction. IEF of microsomal membrane-bound cytochrome P450s has historically been hindered by their solubilization and to our knowledge this is the first report of successful two-dimensional electrophoresis of human liver microsomal cytochrome P450. The procedure we utilized basically followed the protocol developed by Bonfils and Combalbert (72) for rabbit liver microsomal cytochrome P450 3b and 3c. The solubilization and disruption of the microsomal membrane was accomplished with sample buffer containing two detergents, Tergitol NP-10 (2%) and CHAPS (0.5%), and 9.5 M urea and 5% β-mercaptoethanol. Initially, a wide pH range for IEF was used with the intention of narrowing the range when the appropriate interval was determined. However, this was not needed because of the successful separation of CYP1A1 and CYP2E1 under the initial conditions. Surprisingly, the two cytochromes focused isoelectrically very similarly, but their migration through the subsequent SDS-PAGE gel was considerably different. This migrational effect was most likely a result of the high urea concentration, since previously urea has been shown to be capable of altering the migration of proteins in SDS-PAGE gels (79, 80) .
The standards for CYP1A1 and CYP2E1 were microsomal preparations from a lymphoblastoid cell line (AHH-1 TK ϩ/-) expressing either human CYP1A1 or CYP2E1. These cells were chosen over purified proteins as standards based both on the availability and the desire to have sample-standard homogeneity with respect to preparation (i.e. microsomal). A purified protein standard would lack the solubilization problems of microsomal preparations and may display different isoelectric migration characteristics. Indeed, the microsomal standard for CYP1A1 from the AHH-1 TK ϩ/-cell line elicited a similar two-dimensional immunoblot profile to human liver microsomes when probed with mAb 1-12-3 ( Figure 9 ). This profile differed from both profiles observed with a microsomal standard for CYP2E1 from the AHH-1 TK ϩ/-cell line and human liver microsomes when probed with a polyclonal antibody for CYP2E1. Moreover, the two CYP2E1 profiles obtained matched one another very well. Additionally, the shape of the detected spots for the CYP1A1 protein standard and human liver microsomes, when probed with mAb 1-12-3, were very similar and distinct from the shape obtained with CYP2E1 protein. The pattern for CYP1A1 was a very concise circular spot, while the pattern for CYP2E1 was more elongated and stretched out. Thus, the conditions of IEF appeared more suitable for CYP1A1 than CYP2E1, but, nonetheless, optimization of the conditions for CYP2E1 IEF were not necessary for our purpose of separating CYP1A1 and CYP2E1.
The two-dimensional electrophoresis provided strong evidence for the expression of CYP1A1 protein in human liver. The expression appeared to be constitutive, since CYP1A1 protein was detected in all samples studied. Since it is not possible to rule out the possibility that induction of CYP1A1 protein in humans is due to background exposure to PCDDs and related compounds, technically the low levels of CYP1A1 expression may be induced rather than constitutive. Interestingly, the range of CYP1A1 protein expression in the present study (0.4-5 pmol CYP1A1/mg protein) was almost identical to the estimated levels predicted by selective enzyme inhibition studies (81) . Using fluvoxamine and isosafrole as inhibitors of EROD activity, the level of CYP1A1 protein in four human liver samples was estimated by Pastrakuljic et al. as ranging from 0.4 to 2.7 pmol CYP1A1/mg protein. Additional support for CYP1A1 expression in human liver is derived from reports of the detection of CYP1A1 mRNA in human liver (54, 58) . The levels of CYP1A1 mRNA varied~14-and 20-fold between individuals in these studies and correlates well with thẽ 12.5-fold variation we observed in CYP1A1 protein expression.
There are a few plausible reasons why our laboratory, in contrast to numerous others, was able to detect expression of CYP1A1 protein in human liver. The possibilities mainly focus on the issues of sensitivity and specificity. The combination of chemiluminescent detection and mAb 1-12-3 resulted in a highly sensitive system in western immunoblotting, routinely detecting as low as 0.01-0.025 pmol CYP1A1 protein per lane. This sensitivity is at least an order of magnitude greater than the 0.5 pmol sensitivity reported in other studies. Additionally, the lack of a specific antibody for CYP1A1, which does not cross-react with the highly homologous CYP1A2, has previously hindered detection of CYP1A1 protein in human liver. The mAb 1-12-3 utilized in the present study clearly did not cross-react with human CYP1A2 and therefore eliminated this dilemma.
The low level expression of CYP1A1 protein in human liver may not by itself raise concern, but the possible inducibility of this cytochrome by PCDDs and related environmental pollutants is of significant interest. In order to evaluate the potential for induction of CYP1A1 in human liver we utilized precisioncut human liver slices in dynamic organ culture, a recently validated in vitro model for studying CYP1A1 induction (64) . Exposure of human liver slices to TCDD, the prototypical CYP1A1 inducer, resulted in significant induction of CYP1A1 protein, as demonstrated by western immunoblotting with mAb 1-12-3 and the antipeptide anti-human CYP1A1 antibody, as well as induction of EROD activity. The fact that both antibodies recognized an induced protein provides strong evidence for the induction of CYP1A1 protein in human liver. Moreover, while EROD activity can be mediated to differing degrees by both CYP1A1 and CYP1A2 proteins in humans, with recombinant CYP1A1 displaying~10-fold higher activity than CYP1A2 (82), the observed induction of EROD activity in the liver slices was a result of the induction of CYP1A1 protein, since CYP1A2 was unchanged by the experimental conditions used (Figure 7 ). In particular, the variability observed in CYP1A1 induction suggests a possible polymorphic response. However, the variability is unlikely to be due to the previously characterized MspI and exon 7 polymorphisms, since neither the low nor high responsive liver specimens ( Figure 5 ) contained either of the polymorphisms. At the present time there does not appear to be an explanation for the observed difference in inducibility in the two liver specimens. Future studies are directed at characterizing the variability in responsiveness between individuals and the possible molecular mechanisms involved. Precision-cut human liver slices incubated in dynamic organ culture should provide 1366 a unique and valuable in vitro model for addressing these issues, focusing on CYP1A1 induction in humans.
